Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Biosimilars: Adoption Of Global Reference Comparator Would Eliminate Bridging Studies

Executive Summary

Bridging studies conducted between local and foreign versions of the same reference product are redundant, costly and not scientifically necessary for biosimilar development, consultants Christopher Webster and Gillian Woollett write; authors suggest three criteria for global acceptance of a single comparator.

You may also be interested in...



US Comparator Requirement For Interchangeable Biosimilars Would Hurt Industry

US FDA’s recommendation against use of foreign-licensed reference products in clinical switching studies would result in procurement challenges and higher costs for biosimilar developers while also limiting where such studies could be conducted, some companies say.

Make Interchangeability Great Again: Biosimilar Switching Studies Need US Comparators

Sandoz, which used an EU-approved comparator in the switch study for its biosimilar Erelzi, might have to redo the trial in light of FDA’s draft guidance.

Antisense Oligonucleotide Clinical Guidance Emphasizes Individualized Nature Of Treatment

US FDA’ s latest ‘n of 1’ guidance describes clinical considerations for INDs to support dosing and monitoring of an individual with a life-threatening genetic disease who is eligible to receive an ASO; recommendations apply only when a few patients may be candidates for treatment.

Topics

Related Companies

UsernamePublicRestriction

Register

GB002101

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel